Titan Biotech
- Market cap
- ₹ 1,333 Cr.
- P/E
- 53.7x
- P/B
- 9.49x
- 52-week range
- 137.12 – 444.52
- ROE
- 18%
- ROCE
- 23%
- Dividend yield
- 0.1%
- Debt / equity
- 0.03
- Sector
- Chemicals & Petrochemicals
- Industry
- Specialty Chemicals
- Listed on
- BSE
About
Titan Biotech Limited is an India-based manufacturer and exporter of biological products. The Company is a manufacturer of clinically approved collagen (fish, bovine, and chicken), skin care ingredients, bone and joint care ingredients, proteins, animal nutrition ingredients and many more. It can provide any microbiology product that its customers need from powder culture media to prepared media. Its product categories include food ingredients, collagen and proteins, pharmaceuticals and nutraceuticals, animal nutrition, probiotics and fermentation ingredients, agriculture products, and culture media. The Company's food ingredients include flavoring and food preservative and improvers. Its collagen and proteins include wheat protein hydrolysate and collagen peptides. Its nutraceuticals include milk protein and bovine cartilage extract. Its animal nutrition includes binding agent, chelates minerals and yeast. Its agriculture products include bio fungicide, insecticides and acaricides.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Specialty Chemicals: 130 companies →Titan Biotech against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)53.7 against a typical 25.8: pricier than most peers (1st = cheapest).101st of 129
- Sales growth+28.3% against a typical +25.9% from a year earlier.51st of 112
- Profit growth+57.1% against a typical +42.4% from a year earlier.44th of 102
- Share price, 3 months+6.2% against a typical −5.8%.34th of 118
- Size₹ 1,333.1 Cr. market value against a typical ₹ 359.6 Cr. (1st = largest).40th of 126
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 43 | 46 | 40 | 43 | 40 | 38 | 35 | 46 | 54 | 57 | 49 | 59 |
| Expenses | 35 | 35 | 33 | 35 | 32 | 33 | 31 | 38 | 45 | 46 | 39 | 47 |
| Operating Profit | 9 | 11 | 7 | 8 | 8 | 5 | 5 | 9 | 9 | 11 | 10 | 12 |
| OPM % | 20% | 23% | 18% | 19% | 19% | 13% | 13% | 19% | 17% | 19% | 20% | 21% |
| Other Income | 1 | 0 | 0 | 1 | 0 | 2 | 1 | 1 | 1 | 1 | 2 | 2 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit before tax | 8 | 10 | 6 | 8 | 7 | 5 | 5 | 8 | 9 | 11 | 10 | 13 |
| Tax % | 26% | 26% | 24% | 24% | 25% | 26% | 25% | 24% | 26% | 26% | 36% | 26% |
| Net Profit | 7 | 7 | 5 | 6 | 7 | 4 | 4 | 7 | 8 | 9 | 7 | 11 |
| EPS in Rs | 1.58 | 1.74 | 1.21 | 1.55 | 1.62 | 1.06 | 0.98 | 1.66 | 1.88 | 2.07 | 1.63 | 2.63 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- 16%
- 5 Years
- 8%
- 3 Years
- 13%
- TTM
- 37%
- 10 Years
- 33%
- 5 Years
- 0%
- 3 Years
- 6%
- TTM
- 54%
- 10 Years
- 49%
- 5 Years
- 43%
- 3 Years
- 76%
- TTM
- —
- 10 Years
- 22%
- 5 Years
- 20%
- 3 Years
- 18%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Titan Biotech | ₹ 356.00 | ₹ 1,333 Cr. | 53.7x | 9.5x | 18% | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 38.4x | 5.6x | 14.2% | 19.1% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 73.3x | 11.5x | 16.2% | 24.3% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 72.7x | 19.2x | 27.1% | 15.3% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 27.6x | 3.3x | 11.8% | 13.7% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 21.2x | 4.2x | 19.7% | 18.5% |
Management
- Prem Shankar Gupta
- Chief Financial Officer
- Charanjit Singh
- Compliance Officer, Company Secretary
- Shivom Singla
- Vice President - Bulk Division, Whole Time Director
- Udit Singla
- Vice President - Media Division, Whole Time Director
- Naresh Kumar Singla
- Managing Director, Executive Director
- Suresh Chand Singla
- Managing Director, Executive Director
- Raja Singla
- Whole-Time Director
Prices are delayed and for information only. Nothing on this page is investment advice.